FTC-146
Phase 1Small molecule
FTC-146 is one of 49 small molecule programs targeting Chronic pain. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Marinol
Jazz PharmaceuticalsApproved
Intuniv
PPromius Pharma, LLC
Approved
Oxycontin
PProtega
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Bendopa
MMerz North America, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FTC-146. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SStanford University